← All trials
NCT06383819
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 8, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Apr 25, 2024
- Last posted
- Apr 25, 2024
- Enrollment
- 392
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NPO Petrovax Pharm LLCLead sponsor
- I.M. Sechenov First Moscow State Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.